Quartz·1 min read·medium
Biogen stock sinks after Alzheimer's drug trial data fails to impress investors
✦AI Summary
Biogen's stock price declined following disappointing mid-stage clinical trial data for its new Alzheimer's drug. The study failed to meet its primary endpoint, with researchers noting that lower doses performed better than higher ones in ways that remain unexplained.
The mid-stage study missed its primary goal, and the drug's lowest dose outperformed higher doses in ways the company cannot yet explain
healthbusinessscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in